2015
Association of hospital volume with readmission rates: a retrospective cross-sectional study
Horwitz LI, Lin Z, Herrin J, Bernheim S, Drye EE, Krumholz HM, Hines HJ, Ross JS. Association of hospital volume with readmission rates: a retrospective cross-sectional study. The BMJ 2015, 350: h447. PMID: 25665806, PMCID: PMC4353286, DOI: 10.1136/bmj.h447.Peer-Reviewed Original ResearchConceptsReadmission ratesHospital volumeRetrospective cross-sectional studyUS acute care hospitalsHospital readmission ratesAcute care hospitalsCross-sectional studyMedical cancer treatmentCare hospitalAdult dischargesHospital characteristicsMedicare feeCancer treatmentHospitalAssociationDaysService dataPatientsCardiovascularGynecologyQuintileNeurology
2012
Discharge disposition disagreements and re-admission risk among older adults: a retrospective cohort study
Dinescu A, Korc-Grodzicki B, Farber J, Ross JS. Discharge disposition disagreements and re-admission risk among older adults: a retrospective cohort study. BMJ Open 2012, 2: e001646. PMID: 23117568, PMCID: PMC3547317, DOI: 10.1136/bmjopen-2012-001646.Peer-Reviewed Original ResearchRetrospective cohort studyHospital dischargeOlder patientsDischarge dispositionClinical teamCohort studyDaily livingInpatient servicesRe-admission riskRe-admission ratesLarge academic medical centerAcademic medical centerAdjusted analysisMean ageMedical CenterPatientsCognitive impairmentHospitalisationMain independent variableOlder adultsTeam recommendationsDaysDischargeHospitalDispositionRegulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies. New England Journal Of Medicine 2012, 366: 2284-2293. PMID: 22591257, PMCID: PMC3504361, DOI: 10.1056/nejmsa1200223.Peer-Reviewed Original ResearchConceptsNovel therapeutic agentsEuropean Medicines AgencyHealth CanadaTherapeutic agentsNew therapeutic agentsMedian lengthTherapeutic comparisonsDrug AdministrationMedicines AgencyNew drug applicationsPrescription Drug User Fee ActNovel therapeuticsDrug applicationFDAUnique agentUnited StatesTotal review timeFirst reviewRegulatory agenciesReview timeDaysAgentsReviewRegulatory reviewVast majority